Mtvr1 Inhibitors
Mtvr1 Inhibitors encompass a broad range of chemical compounds known to influence various biochemical and cellular pathways, ultimately leading to the inhibition of the functional activity of Mtvr1. Staurosporine, a potent kinase inhibitor, acts broadly across kinase families, potentially affecting the phosphorylation state of proteins like Mtvr1, thus impairing its functional status. Similarly, PI3K inhibitors such as LY294002 and Wortmannin disrupt PI3K-dependent signaling, which could be crucial for the activity of Mtvr1, resulting in its functional inhibition. Compounds like U0126 and PD98059 target the MEK enzyme, halting the MAPK/ERK pathway, which could be imperative for the regulation or activation of Mtvr1. Consequently, these MEK inhibitors could indirectly suppress Mtvr1 activity by impeding the necessary signaling cascade.
Other Mtvr1 inhibitors operate via distinct mechanisms but converge on the common outcome of Mtvr1 inhibition. Rapamycin, an mTOR inhibitor, might interfere with cellular processes such as protein synthesis and growth pathways that could regulate Mtvr1. SB203580 and SP600125 exert their inhibitory effects by targeting p38 MAPK andJNK pathways, respectively, which could be linked to the functional control of Mtvr1. The inhibition of these pathways can reduce the activity of proteins that are regulated by or participate in these signaling cascades. Kinase inhibitors like PP2 and Dasatinib act on Src family kinases and Bcr-Abl tyrosine kinase, respectively; their inhibition could lead to a decrease in Mtvr1 activity if it is dependent on the phosphorylation by these kinases. Bortezomib, a proteasome inhibitor, may indirectly influence Mtvr1 activity by disrupting the degradation of upstream regulatory proteins, thereby affecting the signaling equilibrium which Mtvr1 is a part of. Lastly, Sorafenib, a kinase inhibitor targeting Raf, among others, could impact the Raf/MEK/ERK pathway which might be a determinant in the regulation of Mtvr1, leading to its functional inhibition when this pathway is blocked.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A non-selective protein kinase inhibitor that acts on a wide range of kinases. This compound inhibits phosphorylation events that Mtvr1 may rely on for activation or stability. By blocking these kinases, staurosporine can indirectly lead to the reduced functional activity of Mtvr1 by preventing its proper modification necessary for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor. PI3K is involved in the Akt signaling pathway which can regulate a variety of proteins. Inhibition of this pathway can result in reduced activity of downstream proteins that require PI3K signaling for stabilization or activation, potentially including Mtvr1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that works similarly to LY294002 but is irreversible. It can lead to a decrease in the functional activity of Mtvr1 by inhibiting the PI3K-dependent pathways necessary for its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor that prevents the activation of MAPK/ERK pathway. This pathway is crucial for the regulation of numerous proteins. Inhibition of MEK can result in decreased functional activity of proteins that are regulated by the MAPK/ERK pathway, which may include Mtvr1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which leads to the inhibition of the mTORC1 complex, affecting protein synthesis and cell growth. As Mtvr1 may be regulated by pathways involving mTOR, its functional activity could be indirectly inhibited by rapamycin. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can suppress the p38 MAPK signaling pathway. By inhibiting this pathway, SB203580 may indirectly reduce the functional activity of Mtvr1 if it is a downstream effector of this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which specifically blocks the activation of MAPK/ERK pathway. Inhibition of this pathway can lead to decreased functional activity of proteins regulated by it, potentially including Mtvr1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that impedes the JNK signaling pathway. By disrupting this pathway, SP600125 can indirectly inhibit the functional activity of Mtvr1 if it is involved in JNK pathway-regulated processes. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor that can prevent the activation of Src kinases. Since Src kinases are involved in various signaling pathways, inhibition by PP2 can result in reduced functional activity of proteins like Mtvr1 that may depend on Src signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src family kinase and Bcr-Abl tyrosine kinase inhibitor. Dasatinib can indirectly inhibit the activity of Mtvr1 by inhibiting kinases that would otherwise activate or stabilize Mtvr1. | ||||||